[1] |
Chen W,Zheng R,Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
|
[2] |
Wang SK,Zynger DL,Hes O, et al. Discovery and diagnostic value of a novel oncofetal protein: glypican 3[J]. Adv Anat Pathol, 2014, 21(6): 450-460.
|
[3] |
Fu SJ,Qi CY,Xiao WK, et al. Glypican-3 is a potential prognostic biomarker for hepatocellular carcinoma after curative resection[J]. Surgery, 2013, 154(3): 536-544.
|
[4] |
Nieto MA,Huang RY,Jackson RA, et al. EMT: 2016[J]. Cell, 2016, 166(1): 21-45.
|
[5] |
Valastyan S,Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms[J]. Cell, 2011, 147(2): 275-292.
|
[6] |
Haruyama Y,Kataoka H. Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma[J]. World J Gastroenterol, 2016, 22(1): 275-283.
|
[7] |
Ishiguro T,Sano Y,Komatsu SI, et al. An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors[J]. Sci Transl Med, 2017, 9(410). pii: eaal4291.
|
[8] |
Jiang Z,Jiang X,Chen S, et al. Anti-GPC3-CAR T cells suppress the growth of tumor cells in patient-derived xenografts of hepatocellular carcinoma[J]. Front Immunol, 2016, 7: 690.
|
[9] |
Talbot LJ,Bhattacharya SD,Kuo PC. Epithelial-mesenchymal transition, the tumor microenvironment, and metastatic behavior of epithelial malignancies[J]. Int J Biochem Mol Biol, 2012, 3(2): 117-136.
|
[10] |
Gao W,Kim H,Feng M, et al. Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy[J]. Hepatology, 2014, 60(2): 576-587.
|
[11] |
Wu Y,Liu H,Weng H, et al. Glypican-3 promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through ERK signaling pathway[J]. Int J Oncol, 2015, 46(3): 1275-1285.
|
[12] |
Miao HL,Lei CJ,Qiu ZD, et al. MicroRNA-520c-3p inhibits hepatocellular carcinoma cell proliferation and invasion through induction of cell apoptosis by targeting glypican-3[J]. Hepatol Res, 2014, 44(3): 338-348.
|